These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38713827)

  • 1. CAR T-cell Resistance to Oncogenic Transformation.
    Ruella M; June CH
    Blood Cancer Discov; 2024 Jul; 5(4):229-233. PubMed ID: 38713827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
    Feucht J; Abou-El-Enein M
    Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
    Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
    Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 10. Allogeneic CAR-T cells for cancer immunotherapy.
    Chen X; Gao Y; Zhang Y
    Immunotherapy; 2024; 16(16-17):1079-1090. PubMed ID: 39378059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GD2 Target Antigen and CAR T Cells: Does It Take More Than Two to Tango?
    Locatelli F; Quintarelli C
    Clin Cancer Res; 2024 Aug; 30(16):3361-3363. PubMed ID: 38869449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering a solution for allogeneic CAR-T rejection.
    Amini L; Peter L; Schmueck-Henneresse M
    Mol Ther; 2024 Oct; 32(10):3204-3206. PubMed ID: 39265578
    [No Abstract]   [Full Text] [Related]  

  • 13. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology.
    Rotolo A; Atherton MJ
    Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
    Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
    Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-Ts: new perspectives in cancer therapy.
    Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
    FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
    Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
    J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function.
    Salzer B; Schueller CM; Zajc CU; Peters T; Schoeber MA; Kovacic B; Buri MC; Lobner E; Dushek O; Huppa JB; Obinger C; Putz EM; Holter W; Traxlmayr MW; Lehner M
    Nat Commun; 2020 Aug; 11(1):4166. PubMed ID: 32820173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application.
    Minina EP; Dianov DV; Sheetikov SA; Bogolyubova AV
    Biochemistry (Mosc); 2024 May; 89(5):765-783. PubMed ID: 38880641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.